Related Experiment Videos
[Leukocytoclastic vasculitis associated with ticlopidine].
E Pintor1, M Sanmartín, L Azcona
1Instituto Cardiovascular. Hospital Clínico San Carlos. Madrid.
Revista Espanola De Cardiologia
|January 6, 2001
Summary
Ticlopidine plus aspirin is a common treatment to prevent thrombi after coronary stent implantation. A rare adverse effect, leucocytoclastic vasculitis, was observed in a patient receiving ticlopidine.
Area of Science:
- Cardiology
- Dermatology
- Pharmacology
Background:
- Ticlopidine and aspirin combination is the standard treatment to prevent thrombus formation post-intracoronary stent placement.
- Common adverse effects include cutaneous rash, typically maculopapulous, pruritic, and painless.
Observation:
- A case study involving a patient who developed leucocytoclastic vasculitis.
- The vasculitis was associated with the administration of ticlopidine.
Findings:
- Leucocytoclastic vasculitis is a potential, albeit rare, adverse effect of ticlopidine.
- This finding expands the known spectrum of adverse dermatological reactions to ticlopidine.
Implications:
- Clinicians should consider leucocytoclastic vasculitis in the differential diagnosis for patients on ticlopidine presenting with specific cutaneous symptoms.
- Awareness of this rare side effect is crucial for appropriate patient management and treatment adjustments.
- Further research may be warranted to elucidate the precise mechanism linking ticlopidine to vasculitis.